Effects of maternally-derived antibodies on serologic responses to vaccination in kittens.
The optimal vaccination protocol to induce immunity in kittens with maternal antibodies is unknown. The objective of this study was to determine the effects of maternally-derived antibody (MDA) on serologic responses to vaccination in kittens. Vaccination with a modified live virus (MLV) product was more effective than an inactivated (IA) product at inducing protective antibody titers (PAT) against feline panleukopenia virus (FPV). IA vaccination against feline herpesvirus-1 (FHV) and feline calicivirus (FCV) was more effective in the presence of low MDA than high MDA. Among kittens with low MDA, MLV vaccination against FCV was more effective than IA vaccination. A total of 15%, 44% and 4% of kittens had insufficient titers against FPV, FHV and FCV, respectively, at 17 weeks of age. Serologic response to vaccination of kittens varies based on vaccination type and MDA level. In most situations, MLV vaccination should be utilized and protocols continued beyond 14 weeks of age to optimize response by all kittens.
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, USA.
Brian A
BA
Digangi
Julie K
JK
Levy
Brenda
B
Griffin
Michael J
MJ
Reese
Patricia A
PA
Dingman
Sylvia J
SJ
Tucker
Edward J
EJ
Dubovi
D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood; D017250:Caliciviridae Infections / Q000097:blood / Q000517:prevention & control / Q000662:veterinary; D017927:Calicivirus, Feline / Q000276:immunology; D002371:Cat Diseases / Q000097:blood / Q000517:prevention & control*; D002415:Cats; D005254:Feline Panleukopenia / Q000097:blood / Q000517:prevention & control; D028301:Feline Panleukopenia Virus / Q000276:immunology; D005260:Female; D006564:Herpesviridae / Q000276:immunology; D006566:Herpesviridae Infections / Q000097:blood / Q000517:prevention & control / Q000662:veterinary; D007112:Immunity, Maternally-Acquired; D008297:Male; D011897:Random Allocation; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014765:Viral Vaccines